CO2019003255A2 - Composición que comprende una combinación de un anáologo de trh con ácido arúndico y una sal farmacéuticamente aceptable de ácido arúndico - Google Patents

Composición que comprende una combinación de un anáologo de trh con ácido arúndico y una sal farmacéuticamente aceptable de ácido arúndico

Info

Publication number
CO2019003255A2
CO2019003255A2 CONC2019/0003255A CO2019003255A CO2019003255A2 CO 2019003255 A2 CO2019003255 A2 CO 2019003255A2 CO 2019003255 A CO2019003255 A CO 2019003255A CO 2019003255 A2 CO2019003255 A2 CO 2019003255A2
Authority
CO
Colombia
Prior art keywords
composition
aric acid
combination
trh
analogue
Prior art date
Application number
CONC2019/0003255A
Other languages
English (en)
Spanish (es)
Inventor
Michio Yamamura
Narito Tateishi
Original Assignee
Brivention Pharmaceutical Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brivention Pharmaceutical Shanghai Inc filed Critical Brivention Pharmaceutical Shanghai Inc
Publication of CO2019003255A2 publication Critical patent/CO2019003255A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • C07C53/128Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/30Other Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CONC2019/0003255A 2016-10-03 2019-04-01 Composición que comprende una combinación de un anáologo de trh con ácido arúndico y una sal farmacéuticamente aceptable de ácido arúndico CO2019003255A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016195505 2016-10-03
JP2017184731 2017-09-26
PCT/JP2017/034926 WO2018066427A1 (ja) 2016-10-03 2017-09-27 Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Publications (1)

Publication Number Publication Date
CO2019003255A2 true CO2019003255A2 (es) 2019-04-12

Family

ID=61832036

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0003255A CO2019003255A2 (es) 2016-10-03 2019-04-01 Composición que comprende una combinación de un anáologo de trh con ácido arúndico y una sal farmacéuticamente aceptable de ácido arúndico

Country Status (16)

Country Link
US (1) US10828303B2 (enExample)
EP (1) EP3520795B1 (enExample)
JP (2) JP6596697B2 (enExample)
KR (1) KR20190065315A (enExample)
CN (2) CN113559102B (enExample)
AU (1) AU2017340594B2 (enExample)
BR (1) BR112019006429A2 (enExample)
CA (1) CA3039027A1 (enExample)
CO (1) CO2019003255A2 (enExample)
IL (1) IL265688A (enExample)
MX (1) MX2019003837A (enExample)
PH (1) PH12019500636A1 (enExample)
SG (1) SG11201902599SA (enExample)
TW (1) TW201818939A (enExample)
WO (1) WO2018066427A1 (enExample)
ZA (1) ZA201902341B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
IT202000015895A1 (it) 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6223429A (ja) * 1985-07-24 1987-01-31 Ishikawajima Harima Heavy Ind Co Ltd 水素同位体の回収・貯蔵・供給装置
JPS62234029A (ja) * 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
TW248552B (enExample) 1993-06-01 1995-06-01 Onoda Yakuhin Kogyo Kk
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005105722A1 (ja) * 2004-04-28 2005-11-10 Ono Pharmaceutical Co., Ltd. (2r)−2−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
TWI585071B (zh) * 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
PT2443120T (pt) * 2009-06-16 2017-02-08 Rspr Pharma Ab Forma cristalina de pemirolast
CN102786414B (zh) * 2012-08-15 2014-07-16 四川大学 一类用于治疗和/或预防神经退行性相关疾病的化合物

Also Published As

Publication number Publication date
NZ752311A (en) 2020-12-18
JP6596697B2 (ja) 2019-10-30
MX2019003837A (es) 2019-06-24
CN113559102A (zh) 2021-10-29
IL265688A (en) 2019-05-30
US20190240221A1 (en) 2019-08-08
CN113559102B (zh) 2023-01-03
KR20190065315A (ko) 2019-06-11
TW201818939A (zh) 2018-06-01
CA3039027A1 (en) 2018-04-12
ZA201902341B (en) 2020-08-26
CN110267661B (zh) 2021-08-03
JP2019203007A (ja) 2019-11-28
JPWO2018066427A1 (ja) 2019-07-25
EP3520795A1 (en) 2019-08-07
PH12019500636A1 (en) 2019-10-28
BR112019006429A2 (pt) 2019-06-25
AU2017340594A1 (en) 2019-04-18
US10828303B2 (en) 2020-11-10
SG11201902599SA (en) 2019-05-30
CN110267661A (zh) 2019-09-20
EP3520795B1 (en) 2023-06-14
EP3520795A4 (en) 2020-05-13
AU2017340594B2 (en) 2020-09-10
WO2018066427A1 (ja) 2018-04-12

Similar Documents

Publication Publication Date Title
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CR20190445A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
CR20170187A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MX2019001376A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
CO2019007835A2 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
CO2019003255A2 (es) Composición que comprende una combinación de un anáologo de trh con ácido arúndico y una sal farmacéuticamente aceptable de ácido arúndico
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
MX2018005100A (es) Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos.
MX2018013969A (es) Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201990826A1 (ru) Композиция, содержащая комбинацию trh-аналога с арундовой кислотой, и фармацевтически приемлемая соль арундовой кислоты
BR112016030599A8 (pt) novos derivados de aminoalquilbenzotiazepina e suas utilizações
CL2016002842A1 (es) Sales mesilato de s- y r-pirlindol composición farmacéutica que las comprende útiles para el tratamiento de la depresión.